Personalization of treatment of HER2+ breast cancer
Press release (28/05/2018)
A patient’s immune response makes it possible to personalize treatment of HER2 positive breast cancer.
Brussels, 28 of May 2018 - Researchers at the Jules Bordet Institute published last week, in the Journal of the National Cancer Institute, a study permitting the advance identification, among women suffering from an HER2-positive breast cancer, of those who will and will not respond positively to…
(read more)